Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) represents a prevalent condition within the male genitourinary system. CP/CPPS occurs in men of varying ages, with an increasing recurrence rate associated with advancing age. The pathogenesis of CP/CPPS remains unclear, and clinical treatment typically focuses on symptom management with limited efficacy, resulting in significant economic and psychological burdens for patients. Research has increasingly identified several factors potentially associated with the development of CP/CPPS, including lifestyle, psychosocial influences, neuroendocrine elements, and other variables. This paper reviews recent studies on the risk factors and etiological mechanisms of CP/CPPS to enhance understanding of its mechanisms, providing a reference framework for future basic research and clinical diagnosis and treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.intimp.2025.114128 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Study progress of etiologic mechanisms of chronic prostatitis/chronic pelvic pain syndrome.
Int Immunopharmacol
January 2025
The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China; Department of Urology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China. Electronic address:
Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) represents a prevalent condition within the male genitourinary system. CP/CPPS occurs in men of varying ages, with an increasing recurrence rate associated with advancing age. The pathogenesis of CP/CPPS remains unclear, and clinical treatment typically focuses on symptom management with limited efficacy, resulting in significant economic and psychological burdens for patients.
View Article and Find Full Text PDFSafety and efficacy of extracorporeal shockwave therapy on chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, double-blind, placebo-controlled study.
Prostate Int
December 2024
Department of Urology, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Purpose: This study aimed to investigate the efficacy and safety of extracorporeal shock wave therapy (ESWT) over an 8-week period in individuals diagnosed with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) compared to a control group.
Materials And Methods: This prospective, double-blind, placebo-controlled study enrolled 46 participants diagnosed with CP/CPPS, who were randomly assigned to either the treatment group or the control group in a 2:1 ratio. In the treatment group, ESWT was administered at the perineum once a week for 8 weeks.
Effectiveness of Extended-Release Bupropion and Duloxetine on Pelvic Pain and Sexual Function among Patients with Chronic Prostatitis/Chronic Pelvic Pain.
Adv Biomed Res
October 2024
Department of Psychiatry, Psychosomatic Research Center, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Background: This study aimed to compare the efficacy of the two antidepressants, duloxetine and bupropion, on pelvic pain in patients with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS).
Materials And Methods: This single-blind clinical trial was conducted on 68 CP/CPPS patients. The patients with CP/CPPS received either an extended-release formulation of 150 mg/day bupropion (bupropion group) or duloxetine 30 mg/day for 12 weeks (duloxetine group).
Relationship of Sex and Diagnosis With Symptoms and Illness Impact in Urologic Chronic Pelvic Pain; A Mapp Network Analysis.
Neurourol Urodyn
December 2024
Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Objective: To assess differences in clinical presentation and illness impact in men and women presenting with urologic chronic pelvic pain syndrome (UCPPS) and between men diagnosed with interstitial cystitis/bladder pain syndrome (IC/BPS) or chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS).
Methods: 356 men and 605 women from six sites across the United States were assessed using a comprehensive set of demographic, symptom, and illness impact measures. Multivariable regression analyses examined differences between men and women and between men previously diagnosed with CP/CPPS or IC/BPS.
NLRP3 inflammasome in expressed prostatic secretions as a potential biomarker of chronic prostatitis/chronic pelvic pain syndrome.
Adv Clin Exp Med
December 2024
Department of Urology, Tianjin Medical University Baodi Hospital, China.
Background: Pyroptosis has been implicated in the progression of chronic prostatitis (CP)/chronic pelvic pain syndrome (CPPS).
Objectives: The present study was performed to explore the diagnostic value of the levels of the pyroptosis-related protein nucleotide-binding oligomerization domain, leucine-rich repeat and pyrin domain-containing 3 (NLRP3) inflammasome in the expressed prostatic secretions (EPS) of patients with CP.
Material And Methods: A total of 167 CP patients, including 85 National Institutes of Health (NIH)-IIIA CP patients and 82 NIH-IIIB CP patients, as well as 80 benign prostatic hyperplasia (BPH) patients and 80 healthy controls, were enrolled.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!